Search

Search Constraints

You searched for: Author/Creator Garidel, Patrick

Search Results

1. Subvisible (2–100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Issue 6 (November 2015)

4. Adaption of human antibody λ and κ light chain architectures to CDR repertoires. Issue 3 (19th September 2019)

5. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain. Issue 1 (1st January 2020)

8. Prediction and Reduction of the Aggregation of Monoclonal Antibodies. Issue 8 (21st April 2017)

9. Subvisible (2–100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy. Issue 6 (1st April 2015)